MDNA News and Press, Medicenna Therapeutics Corp.

2023-10-30 09:51:11 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Intuitive Machines (NASDAQ: LUNR ) stock fans will want to mark their calendars for Jan. 12, 2024 as the company prepares for a major catalyst. That date marks the opening of a ...

2023-10-30 09:29:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Medicenna Therapeutics (NASDAQ: MDNA ) stock is falling on Monday after the immunotherapy company alerted investors to a delisting notice . Medicenna Therapeutics notes that...

2023-10-27 08:53:15 ET More on Medicenna Therapeutics Medicenna: Presenting Data Next Week Plus A Clinical Update Next Quarter Seeking Alpha’s Quant Rating on Medicenna Therapeutics Historical earnings data for Medicenna Therapeutics Financial informat...

TORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company received ...

New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to report initial results from both the monotherapy and combination arms of the Phase 2 do...

TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38 th Annu...

2023-10-10 09:28:28 ET More on Medicenna Therapeutics: Medicenna: Presenting Data Next Week Plus A Clinical Update Next Quarter Seeking Alpha’s Quant Rating on Medicenna Therapeutics Historical earnings data for Medicenna Therapeutics For further detai...

TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphr...

MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signalling MDNA223 demonstrated superior efficacy and extended survival in multiple immunologically “hot ...

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results fro...